NCT05722275 Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
| NCT ID | NCT05722275 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese Academy of Sciences |
| Condition | Gastric Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2023-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2023-01-01 with a primary completion date of 2023-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Peritoneal metastasis of gastric cancer is difficult to be detected in time, thus delaying treatment. Based on the conventional CT images of gastric cancer, this study plans to develop, improve and validate an intelligent analysis system based on radiomics. By extracting and combining the radiomics features related to peritoneal metastasis of gastric cancer, the intelligent analysis system could predict the risk of peritoneal metastasis, and provide personalized decision suggestions for the treatment of gastric cancer.
Eligibility Criteria
Inclusion Criteria: * (1) diagnosed advanced gastric cancer (≥cT3) by endoscopy-biopsy pathology, combined with CT and/or endoscopic ultrasound; * (2) with both enhanced CT and laparoscopy; * (3) without typical peritoneal metastasis indications in CT (diffuse omental nodules or omental cake, large amount of ascites, obvious irregular thickening with high peritoneal enhancement); * (4) without other evidence of distant metastasis, and no stage IV features on CT. Exclusion Criteria: * (1) previous abdominal surgery; * (2) previous abdominal malignancies or inflammatory diseases; * (3) time intervals between CT and laparoscopy longer than 2 weeks; * (4) CT image artifacts that undermine peritoneal lesion assessment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05722275 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05722275 currently recruiting?
Yes, NCT05722275 is actively recruiting participants. Contact the research team at di.dong@ia.ac.cn for enrollment information.
Where is the NCT05722275 trial being conducted?
This trial is being conducted at Beijing, China, Fuzhou, China, Guangzhou, China, Guangzhou, China and 9 additional locations.
Who is sponsoring the NCT05722275 clinical trial?
NCT05722275 is sponsored by Chinese Academy of Sciences. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.